Mirolyuba Simeonova Ilieva

Dr. Mirolyuba Simeonova Ilieva

Aalborg University, Copenhagen, Hovedstaden, Denmark
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in European Psychiatry
Verified
Journal Article
Closed access
ASA. Sheldrick
A. Sheldrick
SCS. Camara
S. Camara
Mirolyuba Simeonova IlievaMirolyuba Simeonova Ilieva
Mirolyuba Simeonova Ilieva
PRP. Riederer
P. Riederer
TSTanja Maria Sheldrick-Michel
Tanja Maria Sheldrick-Michel
The neurotrophic factors (NTF) hypothesis of depression was postulated nearly a decade ago and is nowadays widely acknowledged. Previous reports suggest that cerebral concentrations of NTF may be reduced in suicide victims who received minimal or no antidepressant pharmacotherapy. Recent evidence suggests that antidepressant treatment may improve or normalise cerebral concentrations of neurotrophic factors. Therefore, we examined the concentration of brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) in different brain regions (cortex, cingulate gyrus, thalamus, hippocampus, putamen and nucleus caudatus) of 21 individuals – 7 patients of which 4 patients with major depressive disorder (MDD) and overall age 86.8 ± 5 years who received antidepressant pharmacotherapy (selective serotonin re-uptake inhibitors [SSRI]; tricyclic antidepressants [TCA]), 3 patients with MDD without antidepressant treatment and overall age 84.3 ± 5 years versus 14 unaffected subjects at age 70.3 ± 13.8. We detected significant elevation of BDNF (parietal cortex) and NT3 (parietal, temporal and occipital cortex, cingulate gyrus, thalamus, putamen and nucleus caudatus regions) in MDD patients who received antidepressant medication compared to MDD untreated patients and controls. Moreover, we detected a significant decrease of NT3 levels in the parietal cortex of patients suffering from MDD non-treated patients without treatment compared to healthy individuals. Although the limited statistical power due to the small sample size in this proof of concept study corroborates data from previous studies, which show that treatment with antidepressants mediates alterations in neuroplasticity via the action of NTF. However, more research using post-mortem brain tissue with larger samples needs to be carried out as well as longitudinal studies to further verify these results.

19 June 2024 in Cells
Verified
Journal Article
Open access
PDF file
Mirolyuba Simeonova IlievaMirolyuba Simeonova Ilieva
Mirolyuba Simeonova Ilieva
Neurological and neuropsychiatric disorders pose substantial challenges to public health, necessitating a comprehensive understanding of the molecular mechanisms underlying their pathogenesis. In recent years, the focus has shifted toward the intricate world of non-coding RNAs (ncRNAs), a class of RNA molecules that do not encode proteins but play pivotal roles in gene regulation and cellular processes. This review explores the emerging significance of ncRNAs in the context of neurological and neuropsychiatric disorders, shedding light on their diverse functions and regulatory mechanisms. The dysregulation of various ncRNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), has been implicated in the pathophysiology of conditions such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, and mood disorders. This review delves into the specific roles these ncRNAs play in modulating key cellular processes, including synaptic plasticity, neuroinflammation, and apoptosis, providing a nuanced understanding of their impact on disease progression. Furthermore, it discusses the potential diagnostic and therapeutic implications of targeting ncRNAs in neurological and neuropsychiatric disorders. The identification of specific ncRNA signatures holds promise for the development of novel biomarkers for early disease detection, while the manipulation of ncRNA expression offers innovative therapeutic avenues. Challenges and future directions in the field are also considered, highlighting the need for continued research to unravel the complexities of ncRNA-mediated regulatory networks in the context of neurological and neuropsychiatric disorders. This review aims to provide a comprehensive overview of the current state of knowledge and stimulate further exploration into the fascinating realm of ncRNAs in the brain’s intricate landscape.

10 January 2018 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
SFSheena Louise Forsberg
Sheena Louise Forsberg
Mirolyuba Simeonova IlievaMirolyuba Simeonova Ilieva
Mirolyuba Simeonova Ilieva
TSTanja Maria Sheldrick-Michel
Tanja Maria Sheldrick-Michel
Autism spectrum disorders (ASD) affect 1 in 68 children in the US according to the Centers for Disease Control and Prevention (CDC). It is characterized by impairments in social interactions and communication, restrictive and repetitive patterns of behaviors, and interests. Owing to disease complexity, only a limited number of treatment options are available mainly for children that alleviate but do not cure the debilitating symptoms. Studies confirm a genetic link, but environmental factors, such as medications, toxins, and maternal infection during pregnancy, as well as birth complications also play a role. Some studies indicate a set of candidate genes with different DNA methylation profiles in ASD compared to healthy individuals. Thus epigenetic alterations could help bridging the gene–environment gap in deciphering the underlying neurobiology of autism. However, epigenome-wide association studies (EWAS) have mainly included a very limited number of postmortem brain samples. Hence, cellular models mimicking brain development in vitro will be of great importance to study the critical epigenetic alterations and when they might happen. This review will give an overview of the state of the art concerning knowledge on epigenetic changes in autism and how new, cutting edge expertise based on three-dimensional (3D) stem cell technology models (brain organoids) can contribute in elucidating the multiple aspects of disease mechanisms.

1 April 2018 in Biological Psychiatry
Verified
Journal Article
Closed access
Mirolyuba Simeonova IlievaMirolyuba Simeonova Ilieva
Mirolyuba Simeonova Ilieva
Asa Fex-SvenningsenAsa Fex-Svenningsen
Asa Fex-Svenningsen
MTMorten Thorsen
Morten Thorsen
TSTanja Maria Sheldrick-Michel
Tanja Maria Sheldrick-Michel

10 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
Mirolyuba Simeonova IlievaMirolyuba Simeonova Ilieva
Mirolyuba Simeonova Ilieva
Riccardo PanellaRiccardo Panella
Riccardo Panella
Shizuka UchidaShizuka Uchida
Shizuka Uchida
Although cardiac tumor formation is rare, accumulating evidence suggests that the two leading causes of deaths, cancers, and cardiovascular diseases are similar in terms of pathogenesis, including angiogenesis, immune responses, and fibrosis. These similarities have led to the creation of new exciting field of study called cardio-oncology. Here, we review the similarities between cancer and cardiovascular disease from the perspective of microRNAs (miRNAs). As miRNAs are well-known regulators of translation by binding to the 3′-untranslated regions (UTRs) of messenger RNAs (mRNAs), we carefully dissect how a specific set of miRNAs are both oncomiRs (miRNAs in cancer) and myomiRs (muscle-related miRNAs). Furthermore, from the standpoint of similar pathogenesis, miRNAs categories related to the similar pathogenesis are discussed; namely, angiomiRs, Immune-miRs, and fibromiRs.

26 May 2022 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
Mirolyuba Simeonova IlievaMirolyuba Simeonova Ilieva
Mirolyuba Simeonova Ilieva
BABlanca Irene Aldana
Blanca Irene Aldana
KVKasper Tore Vinten
Kasper Tore Vinten
SHSonja Hohmann
Sonja Hohmann
TWThomas William Woofenden
Thomas William Woofenden
TSTanja Maria Sheldrick-Michel
Tanja Maria Sheldrick-Michel